Clinical characteristics and outcomes of COMPASS eligible patients in France. An analysis from the REACH Registry - Université Sorbonne Paris Nord Accéder directement au contenu
Article Dans Une Revue Annales de Cardiologie et d'Angéiologie Année : 2020

Clinical characteristics and outcomes of COMPASS eligible patients in France. An analysis from the REACH Registry

Résumé

Background: Following the publication of the COMPASS trial, the European Medicines Agency has approved a regimen of combination of rivaroxaban 2.5mg twice daily and a daily dose of 75-100mg acetylsalicylic acid (ASA) for patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischemic events. However, the applicability of such a therapeutic strategy in France is currently unknown. Aims: To describe the proportion of patients eligible to COMPASS in France, their baseline clinical characteristics and the rate of major adverse cardiovascular events, using the REACH registry. Methods: From the the REduction of Atherothrombosis for Continued Health (REACH) registry database, a large international registry of patients with, or at risk, of atherothrombosis, we analyzed patients included in France with either established CAD and/or PAD and fulfilling the inclusion and exclusion criteria of the COMPASS trial. The ischemic outcome was a composite of cardiovascular (CV) death, myocardial infarction (MI), or stroke, and serious bleeding were defined as haemorrhagic stroke or bleeding leading to hospitalization or transfusion. Results: Among more than 65000 patients enrolled in REACH, 2.012 patients were evaluable and enrolled in France. Among them, 1194 patients (59.3%) were eligible to COMPASS. The main reasons for exclusion of the COMPASS trial, were high bleeding risk (59.1%), anticoagulant use (43.4%), requirement for dual antiplatelet therapy within 1 year of an ACS or PCI (24.7%). In the "COMPASS eligible population", the rate of MACE (CV, MI and stroke) at 4 years follow-up was 13.4% [11.3-15.8], and serious bleeding was 2.5% at 4 years [1.6-3.4]. Patients with polyvascular disease (n=219) had the highest rate of MACE, compared with patients with CAD only and PAD only (19.1% [13.9-26.1] vs. 11.6% [9.1-14.8] vs 13.2% [9.2-18.8], P<0.0001, respectively). Conclusion: The COMPASS therapeutic strategy in France appears to be applicable to more than half of CAD or PAD patients. This population appears at high residual risk of atherothrombotic events, and patients with polyvascular disease experienced the highest rate of events.
Fichier principal
Vignette du fichier
S0003392820300731.pdf (459.49 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03492815 , version 1 (17-10-2022)

Licence

Paternité - Pas d'utilisation commerciale

Identifiants

Citer

A. Darmon, Y. Elbez, D.L. Bhatt, J. Abtan, J.L. Mas, et al.. Clinical characteristics and outcomes of COMPASS eligible patients in France. An analysis from the REACH Registry. Annales de Cardiologie et d'Angéiologie, 2020, 69, pp.158 - 166. ⟨10.1016/j.ancard.2020.07.002⟩. ⟨hal-03492815⟩
14 Consultations
29 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More